









Markets
/
Stocks
/
nasdaq-ptgx
/

Protagonist Therapeutics Inc

PTGX

98.970USD

-3.200-3.13%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

1.45BMarket Cap

LossP/E TTM



Protagonist Therapeutics Inc

98.970

-3.200-3.13%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Protagonist Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Protagonist Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 34 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 112.25.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Protagonist Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

34 / 391

Overall Ranking

129 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Protagonist Therapeutics Inc Highlights

StrengthsRisks

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Growing

The company is in a growing phase, with the latest annual income totaling USD 46.02M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 46.02M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -48.34, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 74.88M shares, decreasing 6.11% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 163.00 shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

112.250

Target Price

+11.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Protagonist Therapeutics Inc is 6.39, ranking 252 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 7.44M, representing a year-over-year decrease of 95.64%, while its net profit experienced a year-over-year decrease of 133.71%.

Score

Industry at a Glance

Previous score

6.39

Change



Financials

8.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.38

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Protagonist Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Protagonist Therapeutics Inc is 4.19, ranking 383 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -48.34, which is -353.97% below the recent high of 122.78 and -5.40% above the recent low of -50.95.

Score

Industry at a Glance

Previous score

4.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 34/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Protagonist Therapeutics Inc is 8.46, ranking 120 out of 391 in the Biotechnology & Medical Research industry. The average price target is 91.00, with a high of 115.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

8.46

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

112.250

Target Price

+11.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Protagonist Therapeutics Inc

PTGX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Protagonist Therapeutics Inc is 9.20, ranking 16 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 107.17 and the support level at 89.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.58

Change

-0.38

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.206

Buy

RSI(14)

56.997

Neutral

STOCH(KDJ)(9,3,3)

66.045

Neutral

ATR(14)

4.855

High Vlolatility

CCI(14)

33.600

Neutral

Williams %R

44.474

Buy

TRIX(12,20)

0.627

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

100.876

Sell

MA10

99.600

Sell

MA20

96.892

Buy

MA50

89.050

Buy

MA100

87.433

Buy

MA200

73.923

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Protagonist Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 119.78%, representing a quarter-over-quarter increase of 4.08%. The largest institutional shareholder is The Vanguard, holding a total of 5.40M shares, representing 8.47% of shares outstanding, with 22.99% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

8.02M

-5.13%

Farallon Capital Management, L.L.C.

6.20M

+0.39%

The Vanguard Group, Inc.

Star Investors

4.25M

-2.33%

RTW Investments L.P.

5.76M

State Street Investment Management (US)

3.17M

-1.30%

Wellington Management Company, LLP

1.91M

+83.90%

UBS Financial Services, Inc.

1.89M

-24.35%

Janus Henderson Investors

1.10M

+146.36%

Johnson & Johnson Innovation-JJDC, Inc.

2.45M

Geode Capital Management, L.L.C.

1.42M

-1.91%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Protagonist Therapeutics Inc is 6.39, ranking 26 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Protagonist Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.